Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TET2 | Q6N021 | 2/20 | 1.00 |
| ▸ | TET1 | Q8NFU7 | 2/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.66 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.66 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | DNA2 | P51530 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.43 |
| ▸ | KDM5A | P29375 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22545416 | 0.88 | TET2 (0.79) | TET2TET1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL1115630 | 0.83 | TET2 (0.71) | TET2TET1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL17237877 | 0.82 | TET2 (0.69) | TET2TET1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL18422928 | 0.81 | TET2 (0.67) | TET2TET1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL22545520 | 0.80 | TET2 (0.66) | TET2TET1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL13381581 | 0.80 | CSNK2A2 (1.00) | TET2TET1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL13310738 | 0.79 | TET2 (0.65) | TET2TET1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL22545420 | 0.78 | TET2 (0.64) | TET2TET1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL965549 | 0.74 | TET2 (0.59) | TET2TET1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL2114977 | 0.74 | ADORA2A (0.67) | TET2TET1CSNK2A2CSNK2BCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024011258-A2 | TISSUE REGENERATIVE MULTI-DRUG COCKTAIL AND APPARATUS FOR DELIVERY THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2024-01-11 | — | — | WO | claimed |
| US-20230023616-A1 | TISSUE REGENERATIVE MULTI-DRUG COCKTAIL AND APPARATUS FOR DELIVERY THEREOF | TRUSTEES OF TUFTS COLLEGE | 2023-01-26 | — | — | US | claimed |
| WO-2021259471-A1 | DERMAL FILLER WITH HIF-1α ACTIVITY MODULATORS | THOR DOMINIK (AT) | 2021-12-30 | — | — | WO | claimed |
| US-11162071-B2 | Compositions and methods for generating hair cells by upregulating JAG-1 | Frequency Therapeutics, Inc. (US) | 2021-11-02 | — | — | US | claimed |
| EP-2327399-A1 | Treatment of hypertension | Fibrogen, Inc. (US) | 2011-06-01 | — | — | EP | claimed |
| EP-1919463-B9 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN INC (US) | 2011-02-02 | — | — | EP | claimed |
| EP-1919463-B1 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN INC (US) | 2010-06-09 | — | — | EP | claimed |
| US-7618940-B2 | Fat regulation | FIBROGEN, INC. (US) | 2009-11-17 | — | — | US | claimed |
| WO-2007146425-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF CHEMOTHERAPY-INDUCED ANEMIA | FIBROGEN, INC. (US) | 2007-12-21 | — | — | WO | claimed |
| US-20060251638-A1 | Cytoprotection through the use of hif hydroxylase inhibitors | FIBROGEN, INC. | 2006-11-09 | — | — | US | claimed |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | WYETH (US) | 2006-09-28 | — | — | US | claimed |
| WO-2006099610-A2 | METHODS OF IDENTIFYING THERAPEUTIC TARGETS FOR THE TREATMENT OF VULVOVAGINAL ATROPHY | WYETH (US) | 2006-09-21 | — | — | WO | claimed |
| WO-2005007192-A2 | CYTOPROTECTION THROUGH THE USE OF HIF HYDROXYLASE INHIBITORS | FIBROGEN, INC. (US) | 2005-01-27 | — | — | WO | claimed |
| EP-4661861-A1 | USE OF HIF-1A STABILIZING AGENTS FOR THE TREATMENT OF TYPE I INTERFERONOPATHIES | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-12-17 | — | — | EP | disclosed |
| EP-4587049-A1 | ADJUVANTS FOR ENHANCING THE IMMUNE RESPONSE | Lankenau Institute for Medical Research (US) | 2025-07-23 | — | — | EP | disclosed |
| WO-2024216269-A1 | ADJUSTABLY STABLE ADHESIVE COMPOSITIONS FOR MEDICAL AND NON-MEDICAL USES, AND RECYCLING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2004052284-A2 | TREATMENT OF DIABETES | FIBROGEN, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004052285-A2 | FAT REGULATION | FIBROGEN, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20030176317-A1 | Stabilization of hypoxia inducible factor (HIF) alpha | FIBROGEN, INC. | 2003-09-18 | — | — | US | disclosed |
| WO-2003049686-A2 | STABILIZATION OF HYPOXIA INDUCIBLE FACTOR (HIF) ALPHA | FIBROGEN, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176317-A1 | Stabilization of hypoxia inducible factor (HIF) alpha | HIF1A, HIF1AN, EGLN2 | TET2 2467/4885TET1 2022/4885CSNK2A2 852/4885 |
| US-11162071-B2 | Compositions and methods for generating hair cells by upregulating JAG-1 | NOTCH1, HES1, NOTCH3 | TET2 875/4885TET1 1121/4885CSNK2A2 3795/4885 |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | DNASE1L3, ANXA4, SERPINA6 | TET2 3678/4885TET1 3376/4885CSNK2A2 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.